Repositori URV

Autor segons l'article: Bikdeli B; Jiménez D; Demelo-Rodriguez P; Galeano-Valle F; Porras JA; Barba R; Ay C; Malý R; Braester A; Imbalzano E; Rosa V; Lecumberri R; Siniscalchi C; Fidalgo Á; Ortiz S; Monreal M

Departament: Medicina i Cirurgia

Autor/s de la URV: Porras Ledantes, Jose Antonio

Paraules clau: Venous thromboembolism Vaccination Sars-cov-2 Covid-19

Resum: Background: Venous thromboembolism (VTE)—including deep vein thrombosis, pulmonary embolism, and cerebral venous sinus thrombosis (CVST)—may occur early after vaccination against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We sought to describe the site, clinical characteristics, and outcomes of VTE after vaccination against SARS-CoV-2. Methods: In a prospective study using the Registro Informatizado de Enfermedad TromboEmbólica (RIETE) platform, patients with VTE 4–30 days after vaccination against SARS-CoV-2 (1 February 2021 through 30 April 2021) were included. VTE patients recruited from the same centers into RIETE in the same months in 2018–2019 were selected as the reference group. All-cause mortality and major bleeding were the main study outcomes. Results: As of 30 April 2020, 102 patients with post-vaccination VTEs had been identified (28 after adenovirus-based vaccination [ChAdOx1 nCov-19; AstraZeneca] and 74 after mRNA-based vaccination [mRNA-1273; Moderna, and BNT162b2; Pfizer]). Compared with 911 historical controls, patients with VTE after adenovirus-based vaccination more frequently had CVST (10.7% vs. 0.4%, p < 0.001) or thrombosis at multiple sites (17.9% vs. 1.3%, p < 0.001), more frequently had thrombocytopenia (40.7% vs. 14.7%, p < 0.001), and had higher 14-day mortality (14.3% vs. 0.7%; odds ratio [OR]: 25.1; 95% confidence interval [CI]: 6.7–94.9) and major bleeding rates (10.3% vs. 1.0%, OR: 12.03, 95% CI: 3.07–47.13). The site of thrombosis, accompanying thrombocytopenia, and 14-day mortality rates were not significantly different for patients with VTE after mRNA-based vaccination, compared with historical controls. Conclusions: Compared with historical controls, VTE after adenovirus-based vaccination against SARS-CoV-2 is accompanied by thrombocytopenia, occurs in unusual sites, and is associated with worse clinical outcomes.

Àrees temàtiques: Zootecnia / recursos pesqueiros Virology Saúde coletiva Química Medicina veterinaria Medicina ii Medicina i Interdisciplinar Infectious diseases Ciências biológicas iii Ciências biológicas ii Ciências biológicas i Ciências ambientais Ciências agrárias i Biotecnología Biodiversidade

Accès a la llicència d'ús: https://creativecommons.org/licenses/by/3.0/es/

Adreça de correu electrònic de l'autor: joseantonio.porras@urv.cat

Identificador de l'autor: 0000-0001-6418-1822

Data d'alta del registre: 2024-09-07

Versió de l'article dipositat: info:eu-repo/semantics/publishedVersion

URL Document de llicència: https://repositori.urv.cat/ca/proteccio-de-dades/

Referència a l'article segons font original: Viruses-Basel. 14 (2):

Referència de l'ítem segons les normes APA: Bikdeli B; Jiménez D; Demelo-Rodriguez P; Galeano-Valle F; Porras JA; Barba R; Ay C; Malý R; Braester A; Imbalzano E; Rosa V; Lecumberri R; Siniscalch (2022). Venous Thrombosis within 30 Days after Vaccination against SARS-CoV-2 in a Multinational Venous Thromboembolism Registry. Viruses-Basel, 14(2), -. DOI: 10.3390/v14020178

Entitat: Universitat Rovira i Virgili

Any de publicació de la revista: 2022

Tipus de publicació: Journal Publications